A case of autoimmune hepatitis following administration of the COVID19 vaccine

A 73-year-old woman developed jaundice 2 days after receiving her second dose of the SARS-CoV-2 vaccine (Pfizer-BioNTech). She had positive antinuclear and antismooth muscle antibodies and an elevated serum immunoglobulin G level. A liver biopsy revealed massive necrosis. Since her drug-induced lymp...

Full description

Saved in:
Bibliographic Details
Published inKanzo Vol. 63; no. 11; pp. 491 - 499
Main Authors Yagi, Sen, Tamai, Junichirou, Watanabe, Takao, Yoshida, Makoto, Tokumoto, Yoshio, Abe, Masanori, Murakami, Kazuki, Satou, Makoto, Niida, Kazuki, Miyamoto, Yuuya, Umeoka, Fumi, Murakami, Hidehiro, Okita, Shunji, Miyaoka, Hiroaki, Okada, Takeshi, Hiasa, Youichi
Format Journal Article
LanguageJapanese
English
Published The Japan Society of Hepatology 01.11.2022
Subjects
acute liver injury
autoimmune hepatitis
COVID19 vaccine
drug-induced liver injury
lymphocyte stimulation test
Online AccessGet full text

Cover

More Information
Summary:A 73-year-old woman developed jaundice 2 days after receiving her second dose of the SARS-CoV-2 vaccine (Pfizer-BioNTech). She had positive antinuclear and antismooth muscle antibodies and an elevated serum immunoglobulin G level. A liver biopsy revealed massive necrosis. Since her drug-induced lymphocyte stimulation test for the SARS-CoV-2 vaccine was positive, a diagnosis of drug-induced liver injury was initially suggested. Liver functionality test showed no improvement of her condition and she was started on prednisolone. After her liver functionality test was normal, a follow-up liver biopsy was performed. It revealed portal lymphoplasmacytic infiltration with interface hepatitis and rosette formation, which confirmed the diagnosis of autoimmune hepatitis.
ISSN:0451-4203
1881-3593
DOI:10.2957/kanzo.63.491